Type 1 1/2 diabetes: Myth or reality?

Rattan Juneja, Jerry P. Palmer

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

The disease process in classical Type 1 diabetes patients (IDDM) is believed to be autoimmune. In contrast, the disease process in classical Type 2 diabetes patients (NIDDM) is not autoimmune and a decreased sensitivity to insulin action is the main abnormality. The clinical distinction of Type 1 diabetes versus Type 2 diabetes is recognized to be imperfect and has limitations. There is a group of individuals (Type 1 1/2 diabetes), who present like typical NIDDM, but have some of the immunological and clinical features of IDDM. We review the current medical literature on Type 1 1/2 diabetes with special reference to its clinical characteristics, natural history and pathophysiology. Since the distinction between these two forms of diabetes may have important therapeutic implications especially with regards to the benefits of insulin therapy in patients with Type 1 1/2 diabetes and because of the need for uniformity in its diagnosis we recommend that both clinical plus biochemical criteria (the presence of ICA and/or GAD Ab, HLA typing and tests to quantify beta cell function) be used to make a diagnosis. Comparative studies in the area of cytokine production, T cell diabetes reactivity and autoantibody clustering between classic Type 1 diabetes and Type 1 1/2 diabetes patients are needed as are studies with the animal model of Type 1 1/2 diabetes, Psammomys obesus.

Original languageEnglish (US)
Pages (from-to)65-83
Number of pages19
JournalAutoimmunity
Volume29
Issue number1
StatePublished - 1999
Externally publishedYes

Fingerprint

Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus
Histocompatibility Testing
Gerbillinae
Natural History
Autoantibodies
Cluster Analysis
Insulin Resistance
Animal Models
Insulin
Cytokines
T-Lymphocytes
Therapeutics

Keywords

  • Autoantibodies
  • Clinical features
  • NIDDM
  • Pathophysiology
  • Type 1 1/2 diabetes

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Juneja, R., & Palmer, J. P. (1999). Type 1 1/2 diabetes: Myth or reality? Autoimmunity, 29(1), 65-83.

Type 1 1/2 diabetes : Myth or reality? / Juneja, Rattan; Palmer, Jerry P.

In: Autoimmunity, Vol. 29, No. 1, 1999, p. 65-83.

Research output: Contribution to journalArticle

Juneja, R & Palmer, JP 1999, 'Type 1 1/2 diabetes: Myth or reality?', Autoimmunity, vol. 29, no. 1, pp. 65-83.
Juneja, Rattan ; Palmer, Jerry P. / Type 1 1/2 diabetes : Myth or reality?. In: Autoimmunity. 1999 ; Vol. 29, No. 1. pp. 65-83.
@article{add66828881843be87a72f40bfa725a3,
title = "Type 1 1/2 diabetes: Myth or reality?",
abstract = "The disease process in classical Type 1 diabetes patients (IDDM) is believed to be autoimmune. In contrast, the disease process in classical Type 2 diabetes patients (NIDDM) is not autoimmune and a decreased sensitivity to insulin action is the main abnormality. The clinical distinction of Type 1 diabetes versus Type 2 diabetes is recognized to be imperfect and has limitations. There is a group of individuals (Type 1 1/2 diabetes), who present like typical NIDDM, but have some of the immunological and clinical features of IDDM. We review the current medical literature on Type 1 1/2 diabetes with special reference to its clinical characteristics, natural history and pathophysiology. Since the distinction between these two forms of diabetes may have important therapeutic implications especially with regards to the benefits of insulin therapy in patients with Type 1 1/2 diabetes and because of the need for uniformity in its diagnosis we recommend that both clinical plus biochemical criteria (the presence of ICA and/or GAD Ab, HLA typing and tests to quantify beta cell function) be used to make a diagnosis. Comparative studies in the area of cytokine production, T cell diabetes reactivity and autoantibody clustering between classic Type 1 diabetes and Type 1 1/2 diabetes patients are needed as are studies with the animal model of Type 1 1/2 diabetes, Psammomys obesus.",
keywords = "Autoantibodies, Clinical features, NIDDM, Pathophysiology, Type 1 1/2 diabetes",
author = "Rattan Juneja and Palmer, {Jerry P.}",
year = "1999",
language = "English (US)",
volume = "29",
pages = "65--83",
journal = "Autoimmunity",
issn = "0891-6934",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Type 1 1/2 diabetes

T2 - Myth or reality?

AU - Juneja, Rattan

AU - Palmer, Jerry P.

PY - 1999

Y1 - 1999

N2 - The disease process in classical Type 1 diabetes patients (IDDM) is believed to be autoimmune. In contrast, the disease process in classical Type 2 diabetes patients (NIDDM) is not autoimmune and a decreased sensitivity to insulin action is the main abnormality. The clinical distinction of Type 1 diabetes versus Type 2 diabetes is recognized to be imperfect and has limitations. There is a group of individuals (Type 1 1/2 diabetes), who present like typical NIDDM, but have some of the immunological and clinical features of IDDM. We review the current medical literature on Type 1 1/2 diabetes with special reference to its clinical characteristics, natural history and pathophysiology. Since the distinction between these two forms of diabetes may have important therapeutic implications especially with regards to the benefits of insulin therapy in patients with Type 1 1/2 diabetes and because of the need for uniformity in its diagnosis we recommend that both clinical plus biochemical criteria (the presence of ICA and/or GAD Ab, HLA typing and tests to quantify beta cell function) be used to make a diagnosis. Comparative studies in the area of cytokine production, T cell diabetes reactivity and autoantibody clustering between classic Type 1 diabetes and Type 1 1/2 diabetes patients are needed as are studies with the animal model of Type 1 1/2 diabetes, Psammomys obesus.

AB - The disease process in classical Type 1 diabetes patients (IDDM) is believed to be autoimmune. In contrast, the disease process in classical Type 2 diabetes patients (NIDDM) is not autoimmune and a decreased sensitivity to insulin action is the main abnormality. The clinical distinction of Type 1 diabetes versus Type 2 diabetes is recognized to be imperfect and has limitations. There is a group of individuals (Type 1 1/2 diabetes), who present like typical NIDDM, but have some of the immunological and clinical features of IDDM. We review the current medical literature on Type 1 1/2 diabetes with special reference to its clinical characteristics, natural history and pathophysiology. Since the distinction between these two forms of diabetes may have important therapeutic implications especially with regards to the benefits of insulin therapy in patients with Type 1 1/2 diabetes and because of the need for uniformity in its diagnosis we recommend that both clinical plus biochemical criteria (the presence of ICA and/or GAD Ab, HLA typing and tests to quantify beta cell function) be used to make a diagnosis. Comparative studies in the area of cytokine production, T cell diabetes reactivity and autoantibody clustering between classic Type 1 diabetes and Type 1 1/2 diabetes patients are needed as are studies with the animal model of Type 1 1/2 diabetes, Psammomys obesus.

KW - Autoantibodies

KW - Clinical features

KW - NIDDM

KW - Pathophysiology

KW - Type 1 1/2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=0032586655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032586655&partnerID=8YFLogxK

M3 - Article

C2 - 10052687

AN - SCOPUS:0032586655

VL - 29

SP - 65

EP - 83

JO - Autoimmunity

JF - Autoimmunity

SN - 0891-6934

IS - 1

ER -